Actelion sees corporate growth in 2009

Actelion has experienced increasing revenues and sales in 2009, according to the pharmaceutical company’s latest financial report.

The healthcare firm’s net revenues for the 12-month period stood at CHF1.8 million (1.1 million pounds), compared to CHF1.5 million the prevous year.

Although an increase in expenses meant the company’s overall income was reduced in the last year, it nevertheless expressed confidence that the firm’s business is expanding, citing the introduction of products such as Zavesca and a new formulation of Tracleer.

Dr Jean-Paul Clozel, chief executive officer of Actelion, stated that the five new products the firm has in its pipeline will help the company to maintain its growth in the coming year.

He added: “I view the outlook for 2010 positively ? [and] I am looking forward to the results of our two pivotal Phase III programs reporting this year.”

Last month, the firm won a recommendation for approval of Zavesca, its Niemann-Pick type C treatment, from the Food and Drug Administration’s endocrinologic and metabolic drugs advisory committee.